HRT and Weight Loss Combined: Why One Alone Won’t Work

I’ve had the same conversation a dozen times in my Chattanooga clinic this year. A patient hands me a printout of six months of GLP-1 injections — real weight loss for the first three months, then a wall. They ask what’s wrong with the medication. Nothing’s wrong with the medication. Nobody ever checked their hormones. And when I ask who’s supposed to do that, the honest answer is usually: a different provider, at a different clinic, who has never seen this chart.

Most GLP-1 prescribers — telehealth or in-person — run one workflow: intake form, weight, prescription, refill. It’s built to move volume, not to look sideways at what else might be working against you. If you’re a woman in perimenopause or a man with declining testosterone, the person writing your GLP-1 script very likely never ordered a hormone panel, because that’s not what their intake form asks for and not what their revenue model rewards.

You did not fail the medication. The medication is doing exactly what it was designed to do. It just isn’t the only system in your body that governs weight, and nobody checked the other one.

GLP-1 receptor agonists work through a well-documented mechanism: they slow gastric emptying, amplify satiety signaling in the hypothalamus, and improve glucose-dependent insulin secretion. Frías et al. (NEJM, 2021), the SURPASS program’s foundational trial, laid out this mechanism clearly for tirzepatide, and the appetite effect is real — patients consistently describe the constant background hum of “food noise” going quiet.

Here’s what that mechanism does not touch: resting metabolic rate suppressed by declining estrogen or testosterone. Perimenopause and andropause both independently lower the metabolic floor a patient is working from, changing how the body partitions calories toward fat storage versus muscle maintenance. A GLP-1 can turn down your appetite perfectly and you’ll still stall if your hormonal baseline is quietly working against the number on the scale.

I want to be precise about what this is and isn’t. This is mechanistic reasoning — two separate, well-established evidence bases (GLP-1 pharmacology and reproductive endocrinology) pointing at the same patient at the same time. It is not a combined-therapy outcomes trial; nobody has run a randomized study proving HRT plus a GLP-1 beats a GLP-1 alone. I’d rather tell you that plainly than let an ad imply a trial that doesn’t exist. What the two evidence bases do support, without controversy, is that a 40-to-60-year-old GLP-1 patient with an untreated hormonal decline is fighting on two fronts while only one is being managed.

That distinction matters more than most patients realize. A telehealth site that markets a “hormone-optimized GLP-1 protocol” as though it’s backed by a clinical trial is misrepresenting the evidence. What I can tell you honestly, from years of reading labs on patients in exactly this age bracket, is that the pattern — GLP-1 compliance without weight response, alongside a hormone panel nobody ordered — repeats often enough that I don’t consider it optional anymore. I check both, every time, before I decide what a stalled patient actually needs next.

I looked at the compounded-GLP-1 telehealth field seriously before building Summit — Amble, Fifty410, OnlineSemaglutide, MEDVi, IvyRx, and the higher-profile names like Marek Health and Trinity/altRx. Every one of them runs a single-issue model. You’re a GLP-1 patient there, or a hormone patient there. Nobody I found runs both service lines under one physician who actually reads the chart across both.

That split isn’t a minor inconvenience. It means your GLP-1 prescriber has no idea what your hormone panel shows, your hormone clinic has no idea what dose you’re titrating, and if your progress stalls, you get told to “talk to your other doctor” — by two different offices, neither of which is looking at the whole picture. I built Summit because I got tired of watching that gap fail patients who’d done everything right on their end.

I’ve had patients drive across Chattanooga between two appointments in the same week — one to adjust an injection dose, one to review hormone labs — and neither provider knew the other existed. Nobody coordinated the two. Nobody caught that the fatigue one clinic was treating with more sleep hygiene advice was actually a testosterone number the other clinic never saw. Fragmented care isn’t just inefficient. It hides the exact signal that would have told either doctor what was actually going on.

I’m Dr. Paul Miranda. I’m a board-certified physician, and at Summit I personally review every chart — GLP-1 dose, hormone panel, and everything in between — for every combined-protocol patient. Not a questionnaire routed through software. Not a nurse queue that hands off to someone else when the case gets complicated.

That means when a GLP-1 plateau shows up, I’m the same person who ordered your labs, the same person who prescribed your estrogen or testosterone, and the same person who adjusts the GLP-1 dose. There’s no handoff, no second waiting room, no explaining your history twice. I built the practice this way because I’m the one who has to answer for the result — not two separate billing entities with no shared chart.

The floor here isn’t marketing language, it’s a compliance fact I hold myself to: full labs before any prescription, dosing adjusted to your actual panel and tolerance, and an honest conversation about what the trial evidence does and doesn’t show before you start.

I’ve watched the pricing on the big telehealth names closely because it’s part of why patients end up frustrated. Ro runs roughly $498/month at maintenance dosing. Hims runs somewhere around $448–$548/month once the introductory pricing expires. Both quote you a low number up front and hand you a very different number a few months in.

Summit’s combined protocol runs on transparent, descending-dose pricing — the price you’re quoted at your starting dose is the pricing structure you’re on, not a teaser rate that jumps once you’re locked in. I priced it that way on purpose. A patient managing both a GLP-1 titration and an HRT protocol shouldn’t also have to budget for a pricing surprise three months from now.

If you’re on a GLP-1 and stalled, and nobody has ever ordered your hormone panel, that’s worth a real look — not a guess, a lab draw and a physician who reads it. If you’re already managing HRT somewhere else and your GLP-1 prescriber has never seen those results, that’s the same gap from the other direction.

I read every chart myself before we start anything, and I’ll tell you honestly if combined treatment doesn’t apply to your case — that’s part of the job, not a sales pitch dressed up as one.

Ready to start? Apply at summitmetabolichealth.com/apply

This post is for educational purposes and does not replace individualized medical evaluation. Weight loss and hormone therapy outcomes vary by patient; the trial data cited here are group averages, not guarantees. Consult with a licensed physician before starting or changing any treatment.